Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Sep 9, 2020 8:17 AM ET

iCAD Hosts Free Virtual Roundtable Event Focusing on Making Informed Decisions for Adopting New AI Solutions and Practical Applications in Healthcare

iCrowd Newswire - Sep 9, 2020

 iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “What is Real AI: Adopting Artificial Intelligence,” on September 15, 2020 at 7 pm ET/4 pm PT. 

“This unique event provides a rare opportunity to learn from leading experts in multiple disciplines hailing from influential companies focused on the criteria for making AI decisions in clinical settings to enhance patient care,” according to Stacey Stevens, President of iCAD, Inc. “As we have seen with the commercial success of ProFound AI following its FDA-clearance in December 2018, demand continues to grow for clinically proven solutions that can streamline workflow and improve outcomes. In recent months the COVID-19 pandemic has severely impacted cancer screening – for many types of cancer, including breast – further underscoring the need for clinicians to be educated about the latest innovations that can increase accuracy and efficiency, which may help to manage the backlog of patients who need to be screened. We are pleased to host this educational event, and to provide a forum for clinicians to learn about the latest in AI technology so they may make more informed decisions with knowledge of the appropriate evaluation criteria when adopting AI technology into their practices.”

The roundtable will feature specialists in AI and cancer screening, including the following leading experts*:             

During the event, panelists will discuss the latest AI solutions for cancer screening and the benefits AI technology offers to clinicians and patients alike. The goal of this event is to educate clinicians about the value of AI in clinical practice, in the era of COVID-19 and moving forward.   

“COVID-19 has laid bare the fragmentation in our healthcare system while highlighting the potential for AI and digital solutions to help us emerge from this crisis. This event will deliver valuable insights about cancer screenings during COVID-19 and address how AI can help clinicians navigate these unchartered waters,” according to Dr. Wood. “We are in a rapidly changing market and events like this can help the medical community synthesize a vast amount of information so clinicians make educated decisions when adopting new technology that can ultimately enhance patient care.” 

This virtual roundtable event is a part of a larger series of webinars hosted by iCAD in recent months.  Previous events featured leading experts in breast cancer detection and treatment, and have examined various aspects of breast cancer care in the era of COVID-19, including risk-adaptive tools and pragmatic solutions for both screening and treatment. To register for an upcoming free event or view a prior event on-demand, visit

*Panelists have been compensated with an honoraria/speaking fee, but are encouraged to provide their own expert opinions and viewpoints. Dr. Wood is a member of iCAD’s Board of Directors.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.i

The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.

For more information, visit and

Media inquiries:
Jessica Burns, iCAD  

Investor Relations:
Jeremy Feffer, LifeSci Advisors

Contact Information:

Jeremy Feffer, LifeSci Advisors

Tags:    Wire, Disclosure Newswire, United States, English